Top

Discover Oncology

Published in:

Open Access 01-12-2023 | Research

MTHFR act as a potential cancer biomarker in immune checkpoints blockades, heterogeneity, tumor microenvironment and immune infiltration

Authors: Jianheng Peng, Zhongjun Wu

Published in: Discover Oncology | Issue 1/2023

Abstract

Purpose

To evaluate the role and landscape of 5-10-Methylenetetrahydrofolate reductase (MTHFR) to immune infiltration, tumor microenvironment, heterogeneity, immune checkpoints blockades, prognostic significance across cancer types.

Methods

Data sets of genomic, transcriptomic and clinic features of MTHFR across > 60,000 patients and up to 44 cancer types were comprehensively analyzed using R software.

Results

Expression of MTHFR gene is significantly lower in 17 tumors and correlated with overall survival (OS), disease-specific survival (DSS), progression-free interval (PFI) in specific tumors. Gene alterations of MTHFR are observed significant differences across tumor types. Expression of MTHFR is negatively correlated with the stemness index (mDNAsi, mRNAsi, DMPsi, ENHsi, EREG-mDNAsi and EREG-mRNAsi) in the most cancers. MTHFR showed significantly correlated with 67 types of immune cell infiltration scores in 44 cancer types by XCELL algorithm. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis are conducted to show the core tumor mechanism and biological process. Correlations between MTHFR and biomarkers of heterogeneity (MSI, TMB, MATH, HRD, LOH, Neoantigen, ploidy and purity) are also significant in specific tumors. MTHFR is significantly positively correlated with biomarkers of immune related genes (CD19, CD274, CD80, CD86) and mismatched repair genes (MLH1, PMS2, MSH2, MSH6, EPCAM, MLH3, PMS1, EXO1) in most cancer types. Receiver Operating Characteristics (ROC) analyses show MTHFR could act as a potential biomarker in anti-PD-1 (nivolumab to melanoma) and anti-CTLA4 (ipilimumab to melanoma) group of ontreatment, in anti-PD-1 (pembrolizumab to melanoma) group of pretreatment. Two immunohistochemistry antibodies HPA076180 and HPA077255 are verified in 20 types of tumor and could be used to detect the expression of MTHFR efficiently in clinic.

Conclusions

MTHFR could predict the response of immune checkpoints blockades, heterogeneity, tumor microenvironment and immune infiltration.

de Visser KE, Joyce JA. The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth. Cancer Cell. 2023;41(3):374–403.PubMedCrossRef

Martínez-Jiménez F, et al. A compendium of mutational cancer driver genes. Nat Rev Cancer. 2020;20(10):555–72.PubMedCrossRef

Bruni D, Angell HK, Galon J. The immune contexture and immunoscore in cancer prognosis and therapeutic efficacy. Nat Rev Cancer. 2020;20(11):662–80.PubMedCrossRef

Turajlic S, et al. Resolving genetic heterogeneity in cancer. Nat Rev Genet. 2019;20(7):404–16.PubMedCrossRef

Morad G, et al. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell. 2021;184(21):5309–37.PubMedPubMedCentralCrossRef

Raghubeer S, Matsha TE. Methylenetetrahydrofolate (MTHFR), the one-carbon cycle, and cardiovascular risks. Nutrients. 2021;13(12):4562.PubMedPubMedCentralCrossRef

Goyette P, et al. Gene structure of human and mouse methylenetetrahydrofolate reductase (MTHFR). Mamm Genome. 1998;9(8):652–6.PubMedCrossRef

Wu M-T, et al. MTHFR knockdown assists cell defense against folate depletion induced chromosome segregation and uracil misincorporation in DNA. Int J Mol Sci. 2021;22(17):9392.PubMedPubMedCentralCrossRef

Dolgin E. The most popular genes in the human genome. Nature. 2017;551(7681):427–31.PubMedCrossRef

10.

Liew S-C, Gupta ED. Methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism: epidemiology, metabolism and the associated diseases. Eur J Med Genet. 2015;58(1):1–10.PubMedCrossRef

11.

Weisberg I, et al. A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab. 1998;64(3):169–72.PubMedCrossRef

12.

Wilcken B, et al. Geographical and ethnic variation of the 677C> T allele of 5, 10 methylenetetrahydrofolate reductase (MTHFR): findings from over 7000 newborns from 16 areas world wide. J Med Genet. 2003;40(8):619–25.PubMedPubMedCentralCrossRef

13.

Yang B, et al. Geographical distribution of MTHFR C677T, A1298C and MTRR A66G gene polymorphisms in China: findings from 15357 adults of Han nationality. PLoS ONE. 2013;8(3): e57917.PubMedPubMedCentralCrossRef

14.

Pieroth R, et al. Folate and its impact on cancer risk. Curr Nutr Rep. 2018;7(3):70–84.PubMedPubMedCentralCrossRef

15.

Coppedè F, et al. Association of polymorphisms in genes involved in one-carbon metabolism with MTHFR methylation levels. Int J Mol Sci. 2019;20(15):3754.PubMedPubMedCentralCrossRef

16.

Bai Y, Ma X, Zhang YH. Systematic review and meta-analysis of the predictive power of MTHFR polymorphisms for pemetrexed drug efficacy and toxicity in non-small cell lung cancer patients. J Chemother. 2022;34(7):472–82. https://doi.org/10.1080/1120009X.2021.2009989.

17.

Petrone I, et al. MTHFR C677T and A1298C polymorphisms in breast cancer, gliomas and gastric cancer: a review. Genes. 2021;12(4):587.PubMedPubMedCentralCrossRef

18.

Kumar P, Rai V. MTHFR C677T polymorphism and risk of esophageal cancer: an updated meta-analysis. Egypt J Med Hum Genet. 2018;19(4):273–84.CrossRef

19.

Raoufi A, et al. Association of MTHFR C677T and A1298C polymorphisms with susceptibility to chronic lymphocytic leukemia: a systematic review and meta-analysis. Iran J Publ Health. 2021;50(1):83.

20.

Su H. Correlation between MTHFR polymorphisms and hepatocellular carcinoma: a meta-analysis. Nutr Cancer. 2019;71(7):1055–60.PubMedCrossRef

21.

Zara-Lopes T, et al. Polymorphisms in MTHFR, MTR, RFC1 and CssS genes involved in folate metabolism and thyroid cancer: a case-control study. Arch Med Sci: AMS. 2019;15(2):522.PubMedPubMedCentralCrossRef

22.

Blum A, Wang P, Zenklusen JC. SnapShot: TCGA-analyzed tumors. Cell. 2018;173(2):530.PubMedCrossRef

23.

Tomczak K, Czerwińska P, Wiznerowicz M. The Cancer genome atlas (TCGA): an immeasurable source of knowledge. Contemp Oncol. 2015;19(1A):A68.

24.

Consortium, G. The genotype-tissue expression (GTEx) pilot analysis: multitissue gene regulation in humans. Science. 2015;348(6235):648–60.CrossRef

25.

Clough E, Barrett T. The gene expression omnibus database. In: Statistical genomics. Springer; 2016. p. 93–110.CrossRef

26.

Chen F, et al. Pan-cancer molecular subtypes revealed by mass-spectrometry-based proteomic characterization of more than 500 human cancers. Nat Commun. 2019;10(1):1–15.CrossRef

27.

Liu J, et al. An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics. Cell. 2018;173(2):400-416. e11.PubMedPubMedCentralCrossRef

28.

Andersen PK, Gill RD. Cox's regression model for counting processes: a large sample study. Ann Stat. 1982;10(4):1100–20.CrossRef

29.

Gao J, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cbioportal. Sci Signal. 2013;6(269):p11–p11.CrossRef

30.

Benjamin D, et al. Calling somatic SNVs and indels with Mutect2. BioRxiv. 2019. https://doi.org/10.1101/861054.CrossRef

31.

Mermel CH, et al. GISTIC2. 0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 2011;12(4):1–14.CrossRef

32.

Malta TM, et al. Machine learning identifies stemness features associated with oncogenic dedifferentiation. Cell. 2018;173(2):338-354. e11.PubMedPubMedCentralCrossRef

33.

Aran D, Hu Z, Butte AJ. xCell: digitally portraying the tissue cellular heterogeneity landscape. Genome Biol. 2017;18(1):1–14.CrossRef

34.

Racle J, et al. Simultaneous enumeration of cancer and immune cell types from bulk tumor gene expression data. elife. 2017;6:e26476.CrossRefPubMedPubMedCentral

35.

Zeng D, et al. IOBR: multi-omics immuno-oncology biological research to decode tumor microenvironment and signatures. Front Immunol. 2021;12:687975.CrossRef

36.

Vésteinn T, Gibbs D, Brown S. The immune landscape of cancer. Immunity. 2018;81(1):105.

37.

Fekete JT, Győrffy B. ROCplot. org Validating predictive biomarkers of chemotherapy/hormonal therapy/anti-HER2 therapy using transcriptomic data of 3,104 breast cancer patients. Int J cancer. 2019;145(11):3140–51.PubMedCrossRef

38.

Zheng H, et al. An absolute human stemness index associated with oncogenic dedifferentiation. Brief Bioinform. 2021;22(2):2151–60.PubMedCrossRef

39.

Bonneville R, et al. Landscape of microsatellite instability across 39 cancer types. JCO Precis Oncol. 2017;1:1–15.

40.

Thorsson V, et al. The immune landscape of cancer. Immunity. 2018;48(4):812-830. e14.PubMedPubMedCentralCrossRef

41.

Nguyen L, et al. Pan-cancer landscape of homologous recombination deficiency. Nat Commun. 2020;11(1):1–12.CrossRef

42.

Luchini C, et al. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach. Ann Oncol. 2019;30(8):1232–43.PubMedCrossRef

43.

Corti C, Sajjadi E, Fusco N. Determination of mismatch repair status in human cancer and its clinical significance: does one size fit all? Adv Anat Pathol. 2019;26(4):270–9.PubMedCrossRef

44.

He L, Shen Y. MTHFR C677T polymorphism and breast, ovarian cancer risk: a meta-analysis of 19,260 patients and 26,364 controls. Onco Targets Ther. 2017;10:227.PubMedPubMedCentralCrossRef

45.

Ganini C, et al. Serine and one-carbon metabolisms bring new therapeutic venues in prostate cancer. Discov Oncol. 2021;12(1):45.PubMedPubMedCentralCrossRef

46.

Morscher RJ, et al. Mitochondrial translation requires folate-dependent tRNA methylation. Nature. 2018;554(7690):128–32.PubMedPubMedCentralCrossRef

47.

Desideri E, Ciccarone F, Ciriolo MR. Targeting glutathione metabolism: partner in crime in anticancer therapy. Nutrients. 2019;11(8):1926.PubMedPubMedCentralCrossRef

48.

Shi X, et al. Cancer stemness associated with prognosis and the efficacy of immunotherapy in adrenocortical carcinoma. Front Oncol. 2021;11:651622.CrossRefPubMedPubMedCentral

49.

Ordoñez R, et al. DNA methylation of enhancer elements in myeloid neoplasms: think outside the promoters? Cancers. 2019;11(10):1424.PubMedPubMedCentralCrossRef

50.

Rönnerblad M, et al. Analysis of the DNA methylome and transcriptome in granulopoiesis reveals timed changes and dynamic enhancer methylation. Blood, J Am Soc Hematol. 2014;123(17):e79–89.

51.

Martínez-Calle N, et al. Epigenomic profiling of myelofibrosis reveals widespread DNA methylation changes in enhancer elements and ZFP36L1 as a potential tumor suppressor gene that is epigenetically regulated. Haematologica. 2019;104(8):1572.PubMedPubMedCentralCrossRef

52.

Zhang Y, Zhang Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol. 2020;17(8):807–21.PubMedPubMedCentralCrossRef

53.

Khunger A, et al. Multimarker scores of Th1 and Th2 immune cellular profiles in peripheral blood predict response and immune related toxicity with CTLA4 blockade and IFNα in melanoma. Transl Oncol. 2021;14(3): 101014.PubMedPubMedCentralCrossRef

54.

Mao X, et al. Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives. Mol Cancer. 2021;20(1):1–30.CrossRef

55.

Yi K, et al. The association between MTHFR polymorphisms and cervical cancer risk: a system review and meta analysis. Arch Gynecol Obstet. 2016;294(3):579–88.PubMedCrossRef

56.

Topalian SL, Taube JM, Pardoll DM. Neoadjuvant checkpoint blockade for cancer immunotherapy. Science. 2020;367(6477):eaax0182.PubMedPubMedCentralCrossRef

57.

Vanderwalde A, et al. Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients. Cancer Med. 2018;7(3):746–56.PubMedPubMedCentralCrossRef

58.

Le DT, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357(6349):409–13.PubMedPubMedCentralCrossRef

59.

Le DT, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509–20.PubMedPubMedCentralCrossRef

60.

Overman MJ. et al. Nivolumab ± ipilimumab in treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC) with and without high microsatellite instability (MSI-H): CheckMate-142 interim results. J Clin Oncol. 2016;34(15_suppl):3501.CrossRef

61.

Vitale I, et al. Intratumoral heterogeneity in cancer progression and response to immunotherapy. Nat Med. 2021;27(2):212–24.PubMedCrossRef

62.

Mroz EA, Rocco JW. MATH, a novel measure of intratumor genetic heterogeneity, is high in poor-outcome classes of head and neck squamous cell carcinoma. Oral Oncol. 2013;49(3):211–5.PubMedCrossRef

63.

Ma D, et al. Clinical and molecular relevance of mutant-allele tumor heterogeneity in breast cancer. Breast Cancer Res Treat. 2017;162(1):39–48.PubMedCrossRef

64.

Zhang J, et al. Gender-related prognostic value and genomic pattern of intra-tumor heterogeneity in colorectal cancer. Carcinogenesis. 2017;38(8):837–46.PubMedPubMedCentralCrossRef

65.

Mao H. Clinical relevance of mutant-allele tumor heterogeneity and lung adenocarcinoma. Ann Transl Med. 2019;7(18):432.PubMedPubMedCentralCrossRef

66.

Hou Y, et al. Prognostic significance of mutant-allele tumor heterogeneity in uterine corpus endometrial carcinoma. Ann Transl Med. 2020;8(6):339.PubMedPubMedCentralCrossRef

67.

Lord CJ, Ashworth A. BRCAness revisited. Nat Rev Cancer. 2016;16(2):110–20.PubMedCrossRef

68.

Mateo J, et al. DNA-repair defects and olaparib in metastatic prostate cancer. N Engl J Med. 2015;373(18):1697–708.PubMedPubMedCentralCrossRef

69.

Ray-Coquard I, et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med. 2019;381(25):2416–28.PubMedCrossRef

Title: MTHFR act as a potential cancer biomarker in immune checkpoints blockades, heterogeneity, tumor microenvironment and immune infiltration
Authors: Jianheng Peng
Zhongjun Wu
Publication date: 01-12-2023
Publisher: Springer US
Published in: Discover Oncology / Issue 1/2023
Print ISSN: 1868-8497
Electronic ISSN: 2730-6011
DOI: https://doi.org/10.1007/s12672-023-00716-0

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2023

Markedly divergent effects of Ouabain on a Temozolomide-resistant (T98G) vs. a Temozolomide-sensitive (LN229) Glioblastoma cell line

ELFN1-AS1 promotes GDF15-mediated immune escape of colorectal cancer from NK cells by facilitating GCN5 and SND1 association

Nomogram development and external validation for predicting overall survival and cancer-specific survival in patients with primary retroperitoneal sarcoma: a retrospective cohort study

A modified melanoma-molGPA scoring model: assessment of survival after and efficacy of different radiotherapy modalities in patients with melanoma brain metastases

Artificial intelligence assisted detection of superficial esophageal squamous cell carcinoma in white-light endoscopic images by using a generalized system

TRAF inhibition drives cancer cell apoptosis and improves retinoic acid sensitivity in multiple cancers models

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials